宫内大麻暴露与新生儿结局的关联:一项基于人群的回顾性队列研究
该研究基于Kaiser Permanente北加州会员2011年1月1日至2020年7月31日的单胎出生数据,纳入364,924名婴儿,其中22,624名(6.2%)存在宫内大麻暴露。调整混杂因素后,宫内大麻暴露与低出生体重、小于胎龄儿、早产(<37周)及新生儿重症监护室入院的 odds 升高相关;作者建议临床医生应向妊娠或计划妊娠者提供咨询。
要点
- 宫内大麻暴露与低出生体重、小于胎龄儿、早产及新生儿重症监护室入院的 odds 升高相关。
- 暴露频率越高,低出生体重和小于胎龄儿的可能性越大,呈剂量反应关系。
- 作者建议临床医生应向妊娠或计划妊娠者咨询产前大麻使用对新生儿健康的潜在不良结局。
核心结论
- 宫内大麻暴露与低出生体重、小于胎龄儿、早产及新生儿重症监护室入院的 likelihood 升高相关。
- 作者建议临床医生应向妊娠或计划妊娠者咨询产前大麻使用相关的潜在不良新生儿健康结局。
研究设计与样本
- 基于人群的回顾性队列研究,纳入Kaiser Permanente北加州会员2011年1月1日至2020年7月31日的单胎出生亲子对。
- 纳入标准为孕妇在常规产前保健(通常在进入保健时)接受大麻使用筛查,数据来自电子健康记录。
- 采用广义估计方程模型,调整社会人口学特征、其他非大麻产前物质使用、医学和精神健康共病及产前保健充分性。
- 宫内大麻暴露定义:自报自怀孕以来使用和/或孕期任何时间尿液毒理学检测大麻阳性(是/否;主要暴露)。
- 使用频率为自报,分为每日、每周、每月或更少、从不或未知(次要暴露)。
主要发现
- 364,924名婴儿中,22,624名(6.2%)存在宫内大麻暴露。
- 调整后,宫内大麻暴露与低出生体重的 odds 升高相关(调整OR 1.20;95%CI 1.12-1.28)。
- 调整后,宫内大麻暴露与小于胎龄儿的 odds 升高相关(调整OR 1.24;95%CI 1.18-1.30)。
- 调整后,宫内大麻暴露与早产(<37周)的 odds 升高相关(调整OR 1.06;95%CI 1.00-1.13),与新生儿重症监护室入院的 odds 升高相关(调整OR 1.06;95%CI 1.01-1.11)。
- 与早产(<34周)的关联提示性(调整OR 1.11;95%CI 1.00-1.23;P=.055),与呼吸支持的关联无统计学意义(调整OR 1.07;95%CI 0.97-1.18)。
临床怎么用
- 作者建议临床医生应向妊娠或计划妊娠者咨询产前大麻使用与潜在不良新生儿健康结局的关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The full spectrum of associations between in utero cannabis exposure and adverse neonatal outcomes is still unclear. OBJECTIVE: This study aimed to evaluate the associations between in utero cannabis exposure and neonatal outcomes. STUDY DESIGN: This population-based retrospective cohort study of singleton births among Kaiser Permanente Northern California members (January 1, 2011-July 31, 2020) included parent-infant dyads in which the pregnant parent was screened for cannabis use as part of standard prenatal care, generally upon entrance into care. Data were ascertained from electronic health records. Generalized estimating equation models were adjusted for sociodemographic characteristics, other non-cannabis prenatal substance use, medical and mental health comorbidities, and adequacy of prenatal care. In utero cannabis exposure was defined as self-reported use since becoming pregnant and/or a positive urine toxicology test for cannabis at any time during pregnancy (yes/no; primary exposure). Frequency of use was self-reported and categorized as daily, weekly, monthly or less, never, or unknown (secondary exposure). Neonatal outcomes included low birthweight, small for gestational age, preterm birth, neonatal intensive care unit admission, and infant respiratory support. RESULTS: Of 364,924 infants, 22,624 (6.2%) were exposed to cannabis in utero. After adjustment for potential confounders, including in utero exposure to other substances, in utero exposure to cannabis was associated with greater odds of low birthweight (adjusted odds ratio, 1.20; 95% confidence interval, 1.12-1.28), small for gestational age (adjusted odds ratio, 1.24; 95% confidence interval, 1.18-1.30), preterm birth (<37 weeks; adjusted odds ratio, 1.06; 95% confidence interval, 1.00-1.13), and neonatal intensive care unit admission (adjusted odds ratio, 1.06; 95% confidence interval, 1.01-1.11). There was a suggestive association with early preterm birth (<34 weeks; adjusted odds ratio, 1.11; 95% confidence interval, 1.00-1.23; P=.055), but no significant association with respiratory support (adjusted odds ratio, 1.07; 95% confidence interval, 0.97-1.18). Dose-response analysis found an increasing likelihood of low birthweight and small for gestational age with increasing frequency of prenatal cannabis use by the pregnant individual. Sensitivity analyses further supported an increased likelihood of low birthweight and small for gestational age, although associations with other outcomes did not reach statistical significance. CONCLUSION: In utero cannabis exposure was associated with increased likelihood of low birthweight, small for gestational age, preterm birth, and neonatal intensive care unit admission. Clinicians should counsel individuals who are pregnant or considering pregnancy about the potential adverse neonatal health outcomes associated with prenatal cannabis use.
引用
- Avalos LA, Adams SR, Alexeeff SE, et al. Neonatal outcomes associated with in utero cannabis exposure: a population-based retrospective cohort study. Am J Obstet Gynecol. 2023. PMID: 38029850. doi:10.1016/j.ajog.2023.11.1232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。